

## Clopidogrel Poor Metabolizer Rules

**Genetic testing has been performed and indicates this patient may be at risk for inadequate anti-platelet response to clopidogrel (Plavix®) therapy**

This patient has been tested for CYP2C19 variants, and has identified the presence of two copies of a risk allele which is associated with poor metabolism of clopidogrel. Poor metabolizers treated with clopidogrel at normal doses exhibit higher rates of stent thrombosis/other cardiovascular events.

(See StarPanel for patient-specific CYP2C19 gene result.)

**Treatment modification is recommended if not otherwise contraindicated:**

- Prescribe prasugrel (EFFIENT) **10 mg** daily and stop clopidogrel (PLAVIX), startdate 10 AM
- Prescribe ticagrelor (BRILINTA) **180 mg** x1 dose, startdate 10 AM, followed by 90 mg twice daily

### Prasugrel should not be given to patients:

- that have a history of stroke or transient ischemic attack \*\*\* Please check StarPanel if unsure
- that are greater than 75 years of age
- whose body weight is less than 60 kg

### Ticagrelor should not be given to patients:

- that have a history of severe hepatic impairment or intracranial bleed \*\*\* Please check StarPanel if unsure

Click here for [more information](#)

**If prasugrel (EFFIENT) or ticagrelor (BRILINTA) are not selected, please choose desired action:**

- Maintain requested daily dose of clopidogrel (PLAVIX) **75 mg** daily, startdate 10AM

Cancel

Order

**NOTE:** The Vanderbilt P&T Committee recommends that prasugrel or ticagrelor replace clopidogrel for poor metabolizers unless contraindicated, if feasible. The guidelines above were developed based on outcome studies of patients who received a drug-eluting stent into a coronary artery.

## Clopidogrel Poor Metabolizer Rules

**Genetic testing has been performed and indicates this patient may be at risk for inadequate anti-platelet response to clopidogrel (Plavix®) therapy**

This patient has been tested for CYP2C19 variants, and has identified the presence of two copies of a risk allele which is associated with poor metabolism of clopidogrel. Poor metabolizers treated with clopidogrel at normal doses exhibit higher rates of stent thrombosis/other cardiovascular events.

(See StarPanel for patient-specific CYP2C19 gene result.)

**Treatment modification is recommended if not otherwise contraindicated:**

- Prescribe prasugrel (EFFIENT) **10 mg** daily and stop clopidogrel (PLAVIX), startdate 10 AM
- Prescribe ticagrelor (BRILINTA) **180 mg** x1 dose, startdate 10 AM, followed by 90 mg twice daily

### Prasugrel should not be given to patients:

- that have a history of stroke or transient ischemic attack \*\*\* Please check StarPanel if unsure
- that are greater than 75 years of age
- whose body weight is less than 60 kg

### Ticagrelor should not be given to patients:

- that have a history of severe hepatic impairment or intracranial bleed \*\*\* Please check StarPanel if unsure

Click here for [more information](#)

**If prasugrel (EFFIENT) or ticagrelor (BRILINTA) are not selected, please choose desired action:**

- Maintain requested daily dose of clopidogrel (PLAVIX) **75 mg** daily, startdate 10AM

Cancel

Order

**NOTE:** The Vanderbilt P&T Committee recommends that prasugrel or ticagrelor replace clopidogrel for poor metabolizers unless contraindicated, if feasible. The guidelines above were developed based on outcome studies of patients who received a drug-eluting stent into a coronary artery.

## Drug-Genome Advisor

Intermediate Metabolizer - clopidogrel (Plavix) - Rare Risk Allele

Substitution recommended due to increased cardiovascular risks

### If not otherwise contraindicated:

- Prescribe prasugrel (Effient) 10 mg daily

#### Prasugrel should not be given to patients:

- history of stroke or transient ischemic attack
- $\geq 75$  years of age [Current patient age: 51]
- with body weight  $< 60$  kg [Current patient weight: 59.0 kg as of 10/12/2012]

- Prescribe ticagrelor (Brilinta) 90 mg twice daily

#### Ticagrelor should not be given to patients:

- history of severe hepatic impairment
- intracranial bleed

- Continue with clopidogrel (Plavix) prescription

#### Primary override reason:

- Contraindicated for prasugrel or ticagrelor
- Potential side effects
- Provider/Patient opts for clopidogrel
- Cost

## Clopidogrel Intermediate Metabolizer Rules

**Genetic testing has been performed and indicates this patient may be at risk for inadequate anti-platelet response to clopidogrel (Plavix®) therapy**

This patient has been tested for CYP2C19 variants, and has identified the presence of one copy of a risk allele which is associated with intermediate metabolism of clopidogrel. Intermediate metabolizers treated with clopidogrel at normal doses exhibit higher rates of stent thrombosis/other cardiovascular events.

(See StarPanel for patient-specific CYP2C19 gene result.)

**Treatment modification is recommended if not otherwise contraindicated:**

- Prescribe prasugrel (EFFIENT) **10 mg** daily and stop clopidogrel (PLAVIX), startdate 10 AM
- Prescribe ticagrelor (BRILINTA) **180 mg** x1 dose, startdate 10 AM, followed by 90 mg twice daily

### Prasugrel should not be given to patients:

- that have a history of stroke or transient ischemic attack \*\*\* Please check StarPanel if unsure
- that are greater than 75 years of age
- whose body weight is less than 60 kg

### Ticagrelor should not be given to patients:

- that have a history of severe hepatic impairment or intracranial bleed \*\*\* Please check StarPanel if unsure

Click here for [more information](#)

**If prasugrel (EFFIENT) or ticagrelor (BRILINTA) are not selected, please choose desired action:**

- Maintain requested daily dose of clopidogrel (PLAVIX) **75 mg** daily, startdate 10AM

Cancel

Order

**NOTE:** The Vanderbilt P&T Committee recommends that prasugrel or ticagrelor replace clopidogrel for intermediate metabolizers unless contraindicated, if feasible. If this is not possible maintain standard dose of clopidogrel. The guidelines above were developed based on outcome studies of patients who received a drug-eluting stent into a coronary artery.

Back

Home

Close